References

Peptide-induced T cell tolerance to prevent autoimmune diabetes in a transgenic mouse model

10.1073/pnas.91.2.444 · 1994 · External reference

Systemic Antigen in the Treatment of T-Cell-Mediated Autoimmune Diseases

10.1016/s0167-5699(97)01171-7 · 1997 · External reference

Antigen specific immunotherapy: Is it a real possibility to combat T-cell medicated autoimmunity?

10.1073/pnas.91.2.437 · 1994 · External reference

Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy

10.1126/science.1279812 · 1992 · External reference

Induction of TH1 and TH2 immunity in neonatal mice

10.1126/science.271.5256.1728 · 1996 · External reference

The role of clonal deletion and anergy in oral tolerance

10.1016/s0923-2494(98)80147-8 · 1997 · External reference

Oral tolerance in the treatment of inflammatory autoimmune diseases

10.1007/s000110050433 · 1999 · External reference

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

10.1146/annurev.iy.12.040194.004113 · 1994 · External reference

Oral tolerance for the treatment of autoimmune diseases

10.1146/annurev.med.48.1.341 · 1997 · External reference

Induction of autoimmune diabetes by oral administration of autoantigen

10.1126/science.274.5293.1707 · 1996 · External reference

EAE: a model for immune intervention with synthetic peptides

10.3109/08830189209061792 · 1992 · External reference

Ablation of ‘tolerance’ and induction of diabetes by virus infection in viral antigen transgenic mice

10.1016/0092-8674(91)90164-t · 1991 · External reference

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response

10.1016/0092-8674(91)90165-u · 1991 · External reference

How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model

10.1016/1074-7613(94)90101-5 · 1994 · External reference

Virus-induced autoimmune diabetes: Most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) CTL

10.2337/diabetes.49.11.1801 · 2000 · External reference

Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM

10.1006/jaut.1997.0131 · 1997 · External reference

Coexpression of B7.1 and viral (self) transgenes in pancreatic β-cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes

10.1016/1074-7613(95)90062-4 · 1995 · External reference

Dendritic cells induce autoimmune diabetes and maintain disease via De Novo formation of local lymphoid tissue

10.1084/jem.188.8.1493 · 1998 · External reference

Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Dbmajor histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes

10.1128/jvi.69.4.2297-2305.1995 · 1995 · External reference

Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection

10.1016/s1074-7613(00)80628-7 · 1998 · External reference

Neither B-lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes

10.4049/jimmunol.165.10.5945 · 2000 · External reference

Autoreactive CD4+ lymphocytes protect from autoimmune diabetes via bystander suppression using the IL-4/STAT6 pathway

10.1016/s1074-7613(00)80121-1 · 1999 · External reference

DNA immunization to prevent autoimmune diabetes

10.1172/jci7209 · 1999 · External reference

Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice

10.1172/jci118919 · 1996 · External reference

In vivo treatment with a MHC Class I-Restricted blocking peptide can prevent virus-induced autoimmune diabetes

10.4049/jimmunol.161.9.5087 · 1998 · External reference

Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection

10.1128/jvi.63.10.4311-4316.1989 · 1989 · External reference

Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice

10.1128/jvi.73.7.5918-5925.1999 · 1999 · External reference

CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge

10.1128/jvi.70.2.1072-1079.1996 · 1996 · External reference

Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology

10.1016/s1074-7613(00)80340-4 · 1997 · External reference

Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses

10.1084/jem.179.6.1933 · 1994 · External reference

Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection

10.1016/s1074-7613(00)80470-7 · 1998 · External reference

In vivo dynamics of anti-viral CD8 T cells responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection

10.1007/978-1-4615-5355-7_14 · 1998 · External reference

Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection

10.1016/s1074-7613(00)80470-7 · 1998 · External reference

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

10.1073/pnas.88.22.10252 · 1991 · External reference